Talphera (TLPH) Upgraded to Buy: Here's What You Should Know
Talphera Inc TLPH
$1.17
▼ -1.68%
($-0.02)
Open
$1.20
Prev Close
$1.19
Day Range
$1.17 – $1.21
52W Range
$0.69 – $1.57
Market Cap
$60.73M
Beta
0.79
EPS (TTM)
$-0.26
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-02-11 |
| Shares Out. | 51,900,000 |
| Website | talphera.com/ ↗ |
| Phone | 16502163500 |
| Employees | 12 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.3M |
| Free Cash Flow | -$12.3M |
| Total Assets | $26.8M |
| Total Liabilities | $12.4M |
| Equity | $14.4M |
About Talphera Inc
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Talphera Inc is a publicly traded company under the ticker symbol TLPH on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-09-01)